Skip to content
OpenCapital
Get started

Bio-Rad Laboratories BIO Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-Sale

Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-Sale at other companies

Lincoln National logo
Lincoln NationalLNC
$2.6B-3.5%
Western Alliance Bancorporation logo
Western Alliance BancorporationWAL
$665.7M-61.1%
Truist Financial logo
Truist FinancialTFC
$4.03B+3.1%
PNC Financial Services logo
PNC Financial ServicesPNC
$1.9B+13.9%
Repligen logo
RepligenRGEN
$66M—
JPMorgan Chase logo
JPMorgan ChaseJPM
$11.71B+9.3%

Other financials

Income statement

See full
Revenue$592.1M+1.1%
Gross profit$309.4M+1.1%
Operating income$34.1M+43.9%
Net income-$527.1M-924%
EPS (diluted)-$19.55-954%

Balance sheet

See full
Cash & equivalents$509.0M-2.7%
Total debt$987.3M-28.4%
Total equity$6.9B+2.6%
Total assets$9.8B+2.8%

Cash flow

See full
Operating cash flow$108.1M-16.8%
CapEx$30.0M-12.8%
Free cash flow$78.1M-18.2%

Valuation

See full
Market cap$7.56B+10.3%
Enterprise value$8.04B+4.2%
P/E44.8×—
P/S2.9×+0.2×

Profitability

See full
Gross margin51.9%-1.6pp
Operating margin8.8%-3.1pp
Net margin6.5%+3.4pp
FCF margin13.8%-0.2pp

Returns & leverage

See full
Return on equity2.5%+1.3pp
Debt / equity0.1×-0.1×
Current ratio3.2×-2.8×

Where this comes from

Reported directly by Bio-Rad Laboratories in its filing.

Tagged under the XBRL concept us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities.

The official record: Bio-Rad Laboratories’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about Bio-Rad Laboratories's proceeds from maturities, prepayments and calls of debt securities, available-for-sale.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Bio-Rad Laboratories's proceeds from maturities, prepayments and calls of debt securities, available-for-sale?
Bio-Rad Laboratories (BIO) reported proceeds from maturities, prepayments and calls of debt securities, available-for-sale of $17.7M in Q1 2026.
How has Bio-Rad Laboratories's proceeds from maturities, prepayments and calls of debt securities, available-for-sale changed year-over-year?
Bio-Rad Laboratories's proceeds from maturities, prepayments and calls of debt securities, available-for-sale decreased by 9.2% year-over-year, from $19.5M to $17.7M.
What is the long-term trend for Bio-Rad Laboratories's proceeds from maturities, prepayments and calls of debt securities, available-for-sale?
Over 4 years (2021 to 2025), Bio-Rad Laboratories's proceeds from maturities, prepayments and calls of debt securities, available-for-sale has grown at a -34.7% compound annual growth rate (CAGR), from $341.36M to $62M.
What does proceeds from maturities, prepayments and calls of debt securities, available-for-sale mean?
This measures cash inflows resulting from the natural maturity or early redemption of debt securities held in the investment portfolio. It indicates the recurring cash generation from the company's fixed-income investment strategy.